BioLineRx Ltd. Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of three primary clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; BL-7010, a novel co-polymer for the treatment of celiac disease and gluten sensitivity; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-8020, an orally available treatment for the hepatitis C virus, and other viral indications; and BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction. It also has a preclinical stage therapeutic candidate, BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas. The company has strategic collaborations with Novartis Pharma AG; Merck; The University of Texas MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech, Inc. to support various Phase Ib studies investigating the companys BL-8040 in combination with the Genentechs Atezolizumab in multiple cancer indications. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.